DCTH Delcath Systems Net Sales Margin

Brandmark of Delcath Systems Inc (DCTH)

Delcath Systems, Inc. (DCTH) partners with oncology centers, offering a unique perfusion therapy for liver metastases. Analyzing the effective sales margins on GURU.Markets reveals the business's resilience, where 6.00 captures the current value of the indicator. Profitability is driven by the sale of consumables without expanding headcount, while the patent protection of the Hepzato Kit creates significant barriers to entry for new players.

DCTH: Delcath Corp Company Net Profitability 07/04/2022 - 11/19/2026

Delcath Corp (DCTH) - metric breakdowns and financial figures

- share price and expert price forecast:
Analysis of all company metrics:Delcath Corp, DCTH
Finished products of Delcath

For Delcath Systems, Inc. (DCTH), which implements high-tech automated chemotherapy dosing systems, the resilience of profits against operating expenses determines the market viability of its innovations. By analyzing the net profit margin, an investor assesses the share of net income in total revenue, allowing for the differentiation of temporary downturns from systemic business degradation and the identification of an entry point that minimizes the risk of capital freeze.

Analysis of competing companies

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|YmAbs - Company Net Profitability|aurabiosciences.com (AURA) - Net Margin|Candel Therapeutics Inc. - Net Profit Rate|Net Margin Accuray Inc.|Net Margin SELLAS Life Sciences Group SLS|Net Sales Margin ACTU|CTOR - Net Margin|Net Sales Margin HURA (TuHURA Biosciences, Inc.)|Net Profit Rate TARA|FATE: Return on Sales by Net Profit|WHWK (aadibio.com) - Net Return on Sales|TCRX (TScan Therapeutics, Inc.) - Return on Sales by Net Profit|Net Margin Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Net Sales Margin|CVM (CEL-SCI Corporation) - Company Net Profitability|Net Sales Margin OSTX|Net Sales Margin Radiopharm Theranostics Ltd (RADX)|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)